ProMIS Neurosciences公司公布的中期分析结果令人瞩目。数据显示,在所有受试者的基因型中——甚至包括ApoE4纯合子这一高风险群体——均未观察到Aria-E现象。这一发现无疑为相关疗法的安全性提供了有力佐证。
ProMIS Neurosciences公司公布的中期分析结果令人瞩目。数据显示,在所有受试者的基因型中——甚至包括ApoE4纯合子这一高风险群体——均未观察到Aria-E现象。这一发现无疑为相关疗法的安全性提供了有力佐证。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.